“…Different to our results, SWOG did find significantly better survival results for the stage subgroup T4N0/1. Other investigators, Choi from Boston and Grunenwald from Paris, have also included IIIB patients into tri-modality protocols (T4 as well as N3), comparable to our trial and that of SWOG [8,9,14]. However, in the Boston study the induction chemoradiotherapy was more intensive with a complex irradiation scheme of combining once-with twice-daily irradiation up to 60 Gy.…”